ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and...
For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire ServicesGreenville, South Carolina, March 07,...
TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a...
KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and...
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
World-leading authorities explore the potential for extending human lifespan on Monday, March 10 at the JW Marriott AustinAUSTIN, Texas, March 07,...
ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,...
TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"),...
EAGLE, Idaho, March 07, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant...
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
BEIJING, March 7, 2025 /PRNewswire/ -- Chinese President Xi Jinping, also general secretary of the Communist Party of China Central Committee...